GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC

GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Acuta Capital Partners

Cormorant Asset Management

RA Capital Management

RTW Investments

Logos Capital

Biotechnology Value Fund

Boxer Capital

BVF Partners

Surveyor Capital

Venrock Healthcare Capital Partners

Verition Fund Management

GH Research plc

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

https://lnkd.in/eEJUSZpQ

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	93K -	1K 98.92%	883K 88,200%	1.87M 111.55%	3.49M 86.83%
accumulated other comprehensive income loss	-12K -	200K 1,766.67%	-5.54M 2,868.50%	-10.44M 88.55%	-10.51M 0.64%
cash and cash equivalents	498K -	5.89M 1,083.73%	276.78M 4,595.10%	165.96M 40.04%	78.42M 52.75%
cash and short term investments	498K -	5.89M 1,083.73%	276.78M 4,595.10%	165.96M 40.04%	161.56M 2.65%
common stock	801K -	871K 8.74%	1.30M 49.37%	1.30M 0%	1.30M 0%
deferred revenue					-3.49M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory			3.01M -	-90K 102.99%	-178K 97.78%
long term debt					631K -
long term investments				85.72M -	61.14M 28.68%
net debt	-498K -	-5.89M 1,083.73%	-276.78M 4,595.10%	-165.96M 40.04%	-78.08M 52.95%
net receivables			48K -	90K 87.50%	178K 97.78%
other assets
other current assets	6K -	17K 183.33%	10K 41.18%	2.59M 25,760.00%	2.53M 2.20%
other current liabilities	11K -	245K 2,127.27%	1.87M 661.63%	2.68M 43.52%	6.36M 137.42%
other liabilities				-1.87M -	-631K 66.22%
other non current assets
other non current liabilities				1.87M -
othertotal stockholders equity		5.43M -	291.45M 5,267.37%	291.45M 0%	292.76M 0.45%
preferred stock					3.35M -
property plant equipment net			82K -	97K 18.29%	1.07M 1,002.06%
retained earnings	-389K -	-835K 114.65%	-10.04M 1,102.04%	-32.49M 223.73%	-67.94M 109.09%
short term debt					343K -
short term investments					83.14M -
tax assets
tax payables
total assets	504K -	5.91M 1,073.02%	279.92M 4,634.84%	254.36M 9.13%	226.30M 11.03%
total current assets	504K -	5.91M 1,073.02%	279.84M 4,633.46%	168.54M 39.77%	164.09M 2.64%
total current liabilities	104K -	246K 136.54%	2.75M 1,017.48%	4.55M 65.37%	6.70M 47.40%
total debt					343K -
total investments				85.72M -	144.28M 68.31%
total liabilities	104K -	246K 136.54%	2.75M 1,017.48%	4.55M 65.37%	6.70M 47.40%
total liabilities and stockholders equity	504K -	5.91M 1,073.02%	279.92M 4,634.84%	254.36M 9.13%	226.30M 11.03%
total non current assets			82K -	85.82M 104,559.76%	62.21M 27.51%
total non current liabilities				1.87M -	631K 66.22%
total stockholders equity	400K -	5.67M 1,316.50%	277.18M 4,791.90%	249.82M 9.87%	218.97M 12.35%

COM:GHRES

GH Research PLC

Last Close

9.62

22/11 21:00

Market Cap

591.56M

Beta: -

Volume Today

61.64K

Avg: -

Preview